THERAPY DOSSIER · th-2cc7d16855a5

Biodegradable conduit of trimethylene carbonate and epsilon-caprolactone containing poly-p-dioxanone microfilaments with longitudinal grooves

Device

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 29174588 ↗2017Reported benefit

Trimethylene carbonate-caprolactone conduit with poly-p-dioxanone microfilaments to promote regeneration after spinal cord injury.

RatSpinal cord injuryUnspecifiedSprague-DawleyFemale (MeSH indexed)Surgical implantation into the spinal cord cavityImplanted immediately after injury in the acute group, or 2 to 5 months after t…

Model: Cervical spinal cord injury with a small 2 to 3 mm cavity in the C3 to C4 segments, treated either acutely or 2 to 5 months after the initial surgery

The conduit supported regeneration of raphespinal and sensory axons after acute injury and mainly sensory axon regeneration after chronic injury, with reduced astrocyte activity and no change in microglial density, without added cells or neurotrophic factors

Extraction: extract · Supplied extraction confidence: 0.55. Machine-extracted fields require source verification.

Loading the evidence…